| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ATP2A2; ATP2B; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2; SERCA2; SR Ca(2+)-ATPase 2; Calcium pump 2; Calcium-transporting ATPase sarcoplasmic reticulum type; slow twitch skeletal muscle isoform; Endoplasmic reticulum class 1/2 Ca(2+) ATPase |
| Entrez GeneID | 488 |
| WB Predicted band size | Calculated MW: 115 kDa; Observed MW: 110,140 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human SERCA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于SERCA2 ATPase抗体的参考文献(示例为虚构，仅作格式参考)：
1. **文献名称**：*Altered SERCA2a expression in heart failure: Role of calcium handling*
**作者**：Smith J, et al.
**摘要**：该研究通过SERCA2特异性抗体检测发现，心力衰竭患者心肌组织中SERCA2a蛋白表达显著降低，提示钙离子调控异常是心功能恶化的关键机制。
2. **文献名称**：*Validation of a novel SERCA2 monoclonal antibody for immunohistochemistry*
**作者**：Li X, et al.
**摘要**：本文报道了一种高特异性SERCA2单克隆抗体的开发与验证，通过Western blot和免疫组化证实其在小鼠和人类骨骼肌组织中的精准定位能力。
3. **文献名称**：*SERCA2 dysfunction in diabetic cardiomyopathy: Insights from antibody-based proteomic analysis*
**作者**：Garcia R, et al.
**摘要**：利用SERCA2抗体结合蛋白质组学技术，研究发现糖尿病心肌病模型中SERCA2的氧化修饰导致其活性下降，为治疗靶点提供了新依据。
(注：实际文献需通过PubMed或学术数据库检索。)
SERCA2 ATPase (Sarco/endoplasmic reticulum Ca²⁺-ATPase 2) is a critical transmembrane enzyme responsible for actively transporting cytosolic calcium ions into the sarco/endoplasmic reticulum (SR/ER), thereby maintaining low cytoplasmic Ca²⁺ levels essential for cellular processes like muscle relaxation, signal transduction, and protein folding. As a member of the P-type ATPase family, SERCA2 undergoes conformational changes during its ATP-dependent catalytic cycle to pump Ca²⁺ against its concentration gradient. It exists in two major isoforms: SERCA2a, predominantly expressed in cardiac and slow-twitch skeletal muscle, and SERCA2b, ubiquitously found in non-muscle tissues. Dysregulation of SERCA2 activity or expression is implicated in various pathologies, including heart failure, diabetes, and neurodegenerative disorders.
Antibodies targeting SERCA2 ATPase are vital tools for studying its expression, localization, and functional alterations in disease models. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research on SERCA2's role in calcium homeostasis and its interactions with regulatory proteins (e.g., phospholamban). Specificity for SERCA2 isoforms is crucial, as differential expression patterns reflect tissue-specific pathophysiology. For instance, reduced SERCA2a levels in cardiomyocytes are linked to impaired contractility in heart failure. Commercial SERCA2 antibodies are typically validated in knockout controls to ensure isoform specificity. Their applications extend to exploring therapeutic interventions, such as gene therapy or pharmacological SERCA2 activation, highlighting their importance in both basic research and translational medicine.
×
